
Exact Sciences (EXAS) Stock Forecast & Price Target
Exact Sciences (EXAS) Analyst Ratings
Bulls say
Exact Sciences has experienced a notable growth trajectory with its Cologuard screening test, which reported a ~14% increase in volumes due to re-screening traction, care gap programs, and expanded ordering providers, contributing to an enhanced revenue guidance for FY'25. The company's strategic investment in sales and marketing, which grew over 20% year-over-year in Q1'25, underscores its commitment to accelerating the adoption of Cologuard Plus, further solidifying its market position. Additionally, the upcoming product launches and pipeline advancements, including the BLUE-C blood-based testing readout and the CancerGuard launch in H2'25, present significant catalysts that could drive future growth.
Bears say
Exact Sciences faces a negative outlook primarily due to concerns regarding its product launches and growth projections. With historical multiples of 11.3x for other diagnostic companies serving as a benchmark, any failure of Exact's products to gain traction could lead to significant reevaluation relative to low-growth peers. Additionally, the introduction of Oncodetect is not anticipated to positively impact the company’s financial guidance for FY'25 and is expected to hinder gross margins in the second half of that year, further exacerbating concerns over profitability.
This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.
Exact Sciences (EXAS) Analyst Forecast & Price Prediction
Start investing in Exact Sciences (EXAS)
Order type
Buy in
Order amount
Est. shares
0 shares